You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Details for New Drug Application (NDA): 213873


✉ Email this page to a colleague

« Back to Dashboard


NDA 213873 describes PROCHLORPERAZINE EDISYLATE, which is a drug marketed by Morton Grove, Amneal, Avet Lifesciences, Caplin, Eugia Pharma, Gland, Hikma, Hospira, Marsam Pharms Llc, Mylan Labs Ltd, Nexus, Sagent, Smith And Nephew, Somerset Theraps Llc, Teva Parenteral, Viwit Pharm, Watson Labs, Wyeth Ayerst, and Alpharma Us Pharms, and is included in twenty-four NDAs. It is available from seventeen suppliers. Additional details are available on the PROCHLORPERAZINE EDISYLATE profile page.

The generic ingredient in PROCHLORPERAZINE EDISYLATE is prochlorperazine edisylate. There are twenty-one drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the prochlorperazine edisylate profile page.
Summary for 213873
Tradename:PROCHLORPERAZINE EDISYLATE
Applicant:Eugia Pharma
Ingredient:prochlorperazine edisylate
Patents:0
Pharmacology for NDA: 213873
Suppliers and Packaging for NDA: 213873
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PROCHLORPERAZINE EDISYLATE prochlorperazine edisylate INJECTABLE;INJECTION 213873 ANDA Eugia US LLC 55150-360 55150-360-01 1 VIAL, MULTI-DOSE in 1 CARTON (55150-360-01) / 2 mL in 1 VIAL, MULTI-DOSE
PROCHLORPERAZINE EDISYLATE prochlorperazine edisylate INJECTABLE;INJECTION 213873 ANDA Eugia US LLC 55150-360 55150-360-25 25 VIAL, MULTI-DOSE in 1 CARTON (55150-360-25) / 2 mL in 1 VIAL, MULTI-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 5MG BASE/ML
Approval Date:Jul 14, 2022TE:APRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links